leadf
logo-loader
viewVolitionRx

VolitionRx CEO highlights 'very strong assay and platform development progress'

VolitionRx Limited's (NYSEAMERICAN:VNRX) president and CEO Cameron Reynolds recaps on what he describes as a year of 'very strong progress' in assay and platform development with its Nu.Q Capture program and epigenetic toolkit Nu.Q Vet.

Heading into 2020, Reynolds says the company's well placed to meet its key milestones - one of which is to advance its large-scale colorectal and lung cancer trials in Europe, Asia and the U.S.

Quick facts: VolitionRx

Price: 2.94 USD

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: $140.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Aquila Resources releases PEA on Back Forty Project in Michigan

Aquila Resources (TSE: AQA-OTCQB: AQARF) CEO Barry Hildred joined Steve Darling from Proactive to share news about the exploration company with operations in Michigan and Wisconsin Hildred discussed their flagship project Back Forty and the fact they have just put out a PEA. He also talks about...

4 hours, 21 minutes ago

2 min read